Serum Carnosine Dipeptidase 1 and Ubiquitin C - Terminal Hydrolase L1 as Markers of Brain Damage in Patients After Carotid Endarterectomy

Marek Ilzecki; Joanna Ilzecka; Stanislaw Przywara; Aneta Grabarska; Piotr Terlecki; Andrzej Stepulak; Shawn Dave; Tomasz Zubilewicz

doi:10.5455/umj.20160713014033

2023, Vol: 9, Issue: 1

9/1Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Copyright Form
Cover Letter
Title Page

Original Research

Ulutas Med J. 2016; 2(3): 132-137

doi: 10.5455/umj.20160713014033

Serum Carnosine Dipeptidase 1 and Ubiquitin C - Terminal Hydrolase L1 as Markers of Brain Damage in Patients After Carotid Endarterectomy

Marek Ilzecki, Joanna Ilzecka, Stanislaw Przywara, Aneta Grabarska, Piotr Terlecki, Andrzej Stepulak, Shawn Dave, Tomasz Zubilewicz.

Cited By: 1

Abstract
Introduction: Carotid endarterectomy (CEA) is the recommended surgical procedure in the prevention of ischemic stroke. However, this procedure may lead to vascular neurological complications. The aim of the study was to measure serum carnosine dipeptidase 1 (CNDP1) and ubiquitin C - terminal hydrolase L1 (UCHL1) as markers of brain damage in patients that underwent CEA due to high-grade internal carotid artery stenosis.
Material and Methods: This study included 25 patients. Blood samples were taken from the antecubital vein at three different intervals (within a 24 hour period prior to CEA, 12 hours following surgery, and 48 hours after surgery). Serum CNDP1 and UCHL1 levels were measured by a commercially available enzyme-linked immunosorbent assay (ELISA).
Results: The study showed that serum CNDP1 and UCHL1 levels were significantly decreased 12 hours after CEA when compared to the level before the surgery. Furthermore, these enzymes levels were normalized 48 hours after CEA.
Conclusion: Data from our study showed that CEA significantly affects serum CNDP1 and UCHL1 levels. Moreover, these enzyme levels seems to reflect a brain ischemia resulting from severe internal carotid artery stenosis in patients undergoing CEA.

Key words: Carnosine dipeptidase 1, carotid endarterectomy, ischemic stroke, ubiquitin C - terminal hydrolase L1

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Marek Ilzecki Articles by Joanna Ilzecka Articles by Stanislaw Przywara Articles by Aneta Grabarska Articles by Piotr Terlecki Articles by Andrzej Stepulak Articles by Shawn Dave Articles by Tomasz Zubilewicz
	on Google
	on Google Scholar

This Article Cited By the following articles

Clusterin as a potential marker of brain ischemia-reperfusion injury in patients undergoing carotid endarterectomy Upsala Journal of Medical Sciences 2019; 124(3): 193.	1

How to Cite this Article

Pubmed Style

Marek Ilzecki, Joanna Ilzecka, Stanislaw Przywara, Aneta Grabarska, Piotr Terlecki, Andrzej Stepulak, Shawn Dave, Tomasz Zubilewicz. Serum Carnosine Dipeptidase 1 and Ubiquitin C - Terminal Hydrolase L1 as Markers of Brain Damage in Patients After Carotid Endarterectomy. Ulutas Med J. 2016; 2(3): 132-137. doi:10.5455/umj.20160713014033

Web Style

Marek Ilzecki, Joanna Ilzecka, Stanislaw Przywara, Aneta Grabarska, Piotr Terlecki, Andrzej Stepulak, Shawn Dave, Tomasz Zubilewicz. Serum Carnosine Dipeptidase 1 and Ubiquitin C - Terminal Hydrolase L1 as Markers of Brain Damage in Patients After Carotid Endarterectomy. https://www.ulutasmedicaljournal.com/?mno=230870 [Access: March 25, 2023]. doi:10.5455/umj.20160713014033

AMA (American Medical Association) Style

Marek Ilzecki, Joanna Ilzecka, Stanislaw Przywara, Aneta Grabarska, Piotr Terlecki, Andrzej Stepulak, Shawn Dave, Tomasz Zubilewicz. Serum Carnosine Dipeptidase 1 and Ubiquitin C - Terminal Hydrolase L1 as Markers of Brain Damage in Patients After Carotid Endarterectomy. Ulutas Med J. 2016; 2(3): 132-137. doi:10.5455/umj.20160713014033

Vancouver/ICMJE Style

Marek Ilzecki, Joanna Ilzecka, Stanislaw Przywara, Aneta Grabarska, Piotr Terlecki, Andrzej Stepulak, Shawn Dave, Tomasz Zubilewicz. Serum Carnosine Dipeptidase 1 and Ubiquitin C - Terminal Hydrolase L1 as Markers of Brain Damage in Patients After Carotid Endarterectomy. Ulutas Med J. (2016), [cited March 25, 2023]; 2(3): 132-137. doi:10.5455/umj.20160713014033

Harvard Style

Marek Ilzecki, Joanna Ilzecka, Stanislaw Przywara, Aneta Grabarska, Piotr Terlecki, Andrzej Stepulak, Shawn Dave, Tomasz Zubilewicz (2016) Serum Carnosine Dipeptidase 1 and Ubiquitin C - Terminal Hydrolase L1 as Markers of Brain Damage in Patients After Carotid Endarterectomy. Ulutas Med J, 2 (3), 132-137. doi:10.5455/umj.20160713014033

Turabian Style

Marek Ilzecki, Joanna Ilzecka, Stanislaw Przywara, Aneta Grabarska, Piotr Terlecki, Andrzej Stepulak, Shawn Dave, Tomasz Zubilewicz. 2016. Serum Carnosine Dipeptidase 1 and Ubiquitin C - Terminal Hydrolase L1 as Markers of Brain Damage in Patients After Carotid Endarterectomy. THE ULUTAS MEDICAL JOURNAL, 2 (3), 132-137. doi:10.5455/umj.20160713014033

Chicago Style

Marek Ilzecki, Joanna Ilzecka, Stanislaw Przywara, Aneta Grabarska, Piotr Terlecki, Andrzej Stepulak, Shawn Dave, Tomasz Zubilewicz. "Serum Carnosine Dipeptidase 1 and Ubiquitin C - Terminal Hydrolase L1 as Markers of Brain Damage in Patients After Carotid Endarterectomy." THE ULUTAS MEDICAL JOURNAL 2 (2016), 132-137. doi:10.5455/umj.20160713014033

MLA (The Modern Language Association) Style

APA (American Psychological Association) Style

Marek Ilzecki, Joanna Ilzecka, Stanislaw Przywara, Aneta Grabarska, Piotr Terlecki, Andrzej Stepulak, Shawn Dave, Tomasz Zubilewicz (2016) Serum Carnosine Dipeptidase 1 and Ubiquitin C - Terminal Hydrolase L1 as Markers of Brain Damage in Patients After Carotid Endarterectomy. THE ULUTAS MEDICAL JOURNAL, 2 (3), 132-137. doi:10.5455/umj.20160713014033

Author Login Reviewer Login About Publisher Editorial Policies Peer Review Policy Editorial & Peer Review Process Author's Rights and Obligations Publication Ethics and Publication Malpractice Statement Conflict of Interest Policy Plagiarism Policy Protection of Research Participants (Statement On Human And Animal Rights)Privacy Policy Corrections, Retractions & Expressions of Concern Self-Archiving Policies Statement of Informed Consent Advertising Policy Terms of Use License Information Copyright Information



Copyright © 2023 THE ULUTAS MEDICAL JOURNAL All Rights Reserved. Subject to change without notice from or liability to THE ULUTAS MEDICAL JOURNAL. For best results, please use Internet Explorer or Google Chrome	Contact Information Journal Owner HAYRİYE ZEHRA ULUTAŞ Phone: +90 (532) 165 96 39 *E-mail: zehrakenanoglu@hotmail.com Address: Alaattin Mah. 30. Ada sok. D11 Blok No:4 Gungor Uydukent Sitesi Antakya/HATAY Editor-In-Chief* KEMAL TURKER ULUTAS, MD, Assc. Prof. Phone: + 90 (555) 491 35 59 *E-mail: drkemalturker@gmail.com Address: Alaattin Mah. 30. Ada sok. D11 Blok No:4 Gungor Uydukent Sitesi Antakya/HATAY Publisher Information* SCOPEMED Publishing Co. - TURKEY E-mail: scopemed@scopemed.org *Web: https://www.scopemed.com/ We welcome your submissions, suggestions, comments, or questions. To reach us, please use one of the methods provided on this page or Email us at ulutasmedicaljournal@gmail.com* We will respond within 48 to 72 hours.

Contact Information

How to cite this article